GHRP-2 and GHRP-6 are first-generation growth hormone releasing peptides that paved the way for modern secretagogues like Ipamorelin. Both stimulate GH release through the ghrelin receptor, but with important differences in side effect profiles — particularly around appetite stimulation, cortisol elevation, and prolactin. Understanding these differences matters for choosing the right peptide for your goals.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Neither is ideal for fat loss due to cortisol and appetite effects. GHRP-6's intense hunger is particularly counterproductive when restricting calories. For fat-loss goals, Ipamorelin with CJC-1295 (no DAC) or Tesamorelin are significantly better choices — clean GH stimulation without appetite stimulation or cortisol elevation.
Shared Mechanism, Different Selectivity
Both GHRP-2 and GHRP-6 are hexapeptides that activate the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, producing a sharp GH pulse within 15–30 minutes of injection. They are often called "first generation" GHRPs because they predate the more selective peptides developed later. Their GH-releasing potency is genuine and well-documented — in clinical studies, both produce GH spikes 2–10x above baseline depending on dose and individual.
The critical shared limitation is non-selectivity. Ghrelin receptor activation triggers not only GH release but also cortisol and prolactin secretion, ACTH elevation, and intense appetite stimulation. These off-target effects are the primary reasons Ipamorelin displaced them in most modern protocols — Ipamorelin produces comparable GH stimulation with minimal cortisol, prolactin, or appetite effects.
Key Differences Between GHRP-2 and GHRP-6
Appetite stimulation: GHRP-6 causes significantly stronger appetite stimulation than GHRP-2 — often described as hunger so intense it is difficult to manage. This is caused by ghrelin receptor-mediated NPY pathway activation in the hypothalamus. GHRP-2 also stimulates appetite but to a lesser degree. For individuals using GHRPs in a fat-loss context, GHRP-6's appetite effect is a major practical problem.
Cortisol elevation: GHRP-2 tends to produce greater cortisol elevation than GHRP-6. Elevated cortisol counteracts some of the anabolic benefits of GH release and can cause mood, sleep, and metabolic issues with chronic use. This makes GHRP-2 problematic for extended cycles, particularly when cortisol management is already a concern.
GH pulse amplitude: Both produce strong GH pulses, with GHRP-2 often cited as slightly more potent per mcg. However, given the greater cortisol elevation with GHRP-2, the net anabolic benefit may be similar to GHRP-6 despite the stronger raw GH pulse.
GHRP-2, GHRP-6, and Ipamorelin: Where the First-Gen Peptides Still Have a Place
Given that Ipamorelin offers comparable GH stimulation with a much cleaner side effect profile, why use GHRP-2 or GHRP-6 at all? A few legitimate reasons:
Cost: GHRP-2 and GHRP-6 are generally cheaper per milligram than Ipamorelin, though the difference has narrowed. For research purposes where absolute purity of GH stimulation is the goal, the cost-per-unit may tip the decision.
Appetite stimulation as a feature: For individuals in a significant caloric surplus attempting aggressive muscle-building phases, GHRP-6's pronounced appetite stimulation can be a useful tool rather than a side effect.
Established research base: As older peptides, GHRP-2 and GHRP-6 have a longer published research record. For researchers who prefer more extensively documented compounds, this may be relevant.
For most individuals with standard body recomposition, recovery, or anti-aging goals, Ipamorelin (ideally stacked with CJC-1295 without DAC) is the superior modern choice. First-generation GHRPs are best understood as precursors that established the science rather than the optimal current tools.
GHRP-2 vs GHRP-6 vs Ipamorelin
| Property | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| GH release potency | High | High | High (with CJC stack) | — |
| Appetite stimulation | Moderate | Strong (significant) | Minimal | — |
| Cortisol elevation | Moderate-high | Moderate | Minimal | — |
| Prolactin elevation | Some | Some | Minimal | — |
| Standard dose | 100–300 mcg | 100–300 mcg | 100–300 mcg | — |
| Best use case | GH research; budget option | Bulking; appetite stimulation needed | General GH optimisation | — |
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Complete Guide
GHRP-2: Growth Hormone Releasing Peptide 2
Frequently Asked Questions
Neither is ideal for fat loss due to cortisol and appetite effects. GHRP-6's intense hunger is particularly counterproductive when restricting calories. For fat-loss goals, Ipamorelin with CJC-1295 (no DAC) or Tesamorelin are significantly better choices — clean GH stimulation without appetite stimulation or cortisol elevation.
Fasted injection is essential — food (especially carbohydrates and fats) substantially blunts the GH pulse. Typical timing: pre-sleep on an empty stomach for maximum overnight GH, or upon waking before breakfast. Combining with a GHRH (CJC-1295 without DAC or Sermorelin) amplifies the GH pulse by working through a complementary receptor pathway.
The prolactin elevation from GHRP-2 and GHRP-6 can theoretically contribute to gynecomastia risk, particularly in individuals already prone to it or using compounds that elevate estrogen. This is a meaningful practical concern that Ipamorelin largely avoids due to minimal prolactin elevation. If using first-generation GHRPs for extended periods, monitoring prolactin levels is advisable.
MK-677 (Ibutamoren) is an oral ghrelin mimetic that also stimulates GH through the ghrelin receptor but is taken orally rather than by injection. Like GHRP-6, it causes significant appetite stimulation and some water retention. Its 24-hour half-life produces sustained GH elevation rather than a discrete pulse, which has different effects on IGF-1 levels and tissue response. For convenience, MK-677 has a clear advantage; for clean pulsatile GH stimulation, Ipamorelin injections are more physiological.
GHRP-6 does improve sleep quality for many users, primarily through the GH pulse it stimulates — GH release during early sleep cycles correlates with deeper slow-wave sleep. However, Ipamorelin is widely considered better for sleep optimisation due to identical GH stimulation without the cortisol elevation that can interfere with sleep architecture.